Key Points
- Neurogene CFO Christine Mikail Cvijic sold 4,200 shares on July 7 at an average price of $36.13, bringing in about $151,746. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The transaction reduced her direct holdings to 84,040 shares, valued at roughly $3.04 million, a 4.76% decrease in her position. The article also notes she sold additional Neurogene shares in several earlier transactions.
- Neurogene shares were trading up 13% to $36.80, near their 52-week high of $37.27. The company recently reported a quarterly EPS loss that missed estimates, while analysts currently rate the stock a Buy on average.
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 600 shares of the firm's stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.02, for a total transaction of $21,612.00. Following the completion of the sale, the chief financial officer owned 88,240 shares of the company's stock, valued at $3,178,404.80. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christine Mikail Cvijic also recently made the following trade(s):
- On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The stock was sold at an average price of $36.13, for a total value of $151,746.00.
- On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total value of $141,404.02.
- On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total value of $25,170.34.
- On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.
Neurogene Trading Up 13.0%
NGNE stock opened at $36.80 on Wednesday. Neurogene Inc. has a 1-year low of $15.93 and a 1-year high of $37.27. The business's 50 day simple moving average is $29.70 and its 200 day simple moving average is $23.57. The firm has a market capitalization of $581.44 million, a PE ratio of -8.09 and a beta of 1.68.
Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.09). As a group, sell-side analysts predict that Neurogene Inc. will post -5.63 EPS for the current fiscal year.
Wall Street Analyst Weigh In
NGNE has been the subject of several research analyst reports. UBS Group set a $70.00 target price on shares of Neurogene in a report on Wednesday, June 3rd. Rodman & Renshaw started coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a "buy" rating and a $70.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Neurogene in a research report on Tuesday, June 9th. Canaccord Genuity Group lowered their target price on Neurogene to $180.00 and set a "buy" rating on the stock in a research note on Monday, April 6th. Finally, Guggenheim initiated coverage on Neurogene in a report on Tuesday, April 28th. They set a "buy" rating and a $69.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $84.83.
Check Out Our Latest Report on NGNE
Hedge Funds Weigh In On Neurogene
Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company's stock worth $36,000 after purchasing an additional 978 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Neurogene during the fourth quarter worth approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock worth $82,000 after purchasing an additional 1,059 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Neurogene in the fourth quarter valued at approximately $165,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Neurogene in the third quarter valued at approximately $187,000. 52.37% of the stock is owned by institutional investors.
About Neurogene
(
Get Free Report)
Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
